Tracer library / [161Tb]Tb-DOTA-LM3

Structure of DOTA-LM3 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 168355559

[161Tb]Tb-DOTA-LM3

Also written as [Tb-161]Tb-DOTA-LM3

Radionuclide: Tb-161 t½ 9907.2 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 2

Neuroendocrine neoplasms Dosimetry and biodistribution studies Peptide receptor radionuclide therapy

What it is

Compound class: DOTA-conjugated somatostatin receptor antagonist peptide
Target / mechanism: Somatostatin receptor (SSTR) antagonist PMID 39046521
Clinical application: Peptide receptor radionuclide therapy of somatostatin receptor-positive neuroendocrine tumours PMID 41381241
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	—	>98%	DOTA-LM3 CSBio, California, US	39046521 2024 Eur J Nucl Med Mol Imaging DOTA-LM3 (CSBio, Silicon Valley Menlo Park, California, United States) and DOTATATE (Bachem, Bubendorf, Switzerland) were labeled with terbium-161 or lutetium-177 at a molar activity of up to 100 MBq/nmol using standard labeling conditions as previously reported
—	—	—	—	≥ 98%	DOTA-LM3	34625828 2022 Eur J Nucl Med Mol Imaging

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
2026 · J Nucl Med · Prospective · Phase 0

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: CSBio
Typical final purification: —

Need this precursor?We can point you to suppliers for [161Tb]Tb-DOTA-LM3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41381241: 'DOTA-LM3'. Stage set/updated at stage 23 from PMID 41381241: 'A Phase 0 Study.'. | Stage 30 (2026-09-18): Stage was 'Phase 0 clinical study'; normalised to 'Clinical research', original wording kept here.